Date: 19-Oct-2021

Dr Reddys Labs Launches Generic BiCNU In US Market

Dr Reddy's Laboratories Ltd. announced the launch of carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU (carmustine for injection) approved by the US Food and Drug Administration (FDA).

The BiCNU brand and generic market had US sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health.

Dr Reddy's Carmustine for injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg carmustine USP and a vial containing 3 mL sterile diluent.